BMRN BioMarin Pharmaceutical Inc.

Price (delayed)

$78.67

Market cap

$14.28B

P/E Ratio

16.7

Dividend/share

N/A

EPS

$4.71

Enterprise value

$14.71B

Sector: Healthcare
Industry: Biotechnology
BioMarin Pharmaceutical, Inc. is a biotechnology company, which engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline include Vosoritide (BMN 111) for Achondroplasia and Valoctocogene Roxaparvovec (BMN 270) for Hemophilia A. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Highlights

The equity has grown by 32% YoY and by 25% from the previous quarter
The revenue has grown by 16% YoY
Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ
The debt has soared by 72% year-on-year
BMRN's gross margin is down by 7% year-on-year and by 6% since the previous quarter

Key stats

What are the main financial stats of BMRN
Market
Shares outstanding
181.53M
Market cap
$14.28B
Enterprise value
$14.71B
Valuations
Price to earnings (P/E)
16.7
Price to book (P/B)
3.52
Price to sales (P/S)
7.65
EV/EBIT
751.77
EV/EBITDA
119.45
EV/Sales
7.9
Earnings
Revenue
$1.86B
EBIT
$19.57M
EBITDA
$123.18M
Free cash flow
$89.18M
Per share
EPS
$4.71
Free cash flow per share
$0.49
Book value per share
$22.35
Revenue per share
$10.28
TBVPS
$30.55
Balance sheet
Total assets
$6.16B
Total liabilities
$2.1B
Debt
$1.45B
Equity
$4.05B
Working capital
$1.88B
Liquidity
Debt to equity
0.36
Current ratio
3.2
Quick ratio
2.24
Net debt/EBITDA
3.51
Margins
EBITDA margin
6.6%
Gross margin
73.5%
Net margin
45.7%
Operating margin
-0.1%
Efficiency
Return on assets
16.3%
Return on equity
25%
Return on invested capital
0.5%
Return on capital employed
0.4%
Return on sales
1.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BMRN stock price

How has the Biomarin Pharmaceutical stock price performed over time
Intraday
-2.15%
1 week
2.12%
1 month
5.7%
1 year
-2.53%
YTD
-6.95%
QTD
3.4%

Financial performance

How have Biomarin Pharmaceutical's revenue and profit performed over time
Revenue
$1.86B
Gross profit
$1.37B
Operating income
-$1.09M
Net income
$852.03M
Gross margin
73.5%
Net margin
45.7%
Biomarin Pharmaceutical's operating margin has plunged by 103% from the previous quarter but it has soared by 99% YoY
The operating income has dropped by 102% since the previous quarter but it has surged by 99% year-on-year
The revenue has grown by 16% YoY
Biomarin Pharmaceutical's gross profit has increased by 8% YoY but it has decreased by 5% QoQ

Growth

What is Biomarin Pharmaceutical's growth rate over time

Valuation

What is Biomarin Pharmaceutical stock price valuation
P/E
16.7
P/B
3.52
P/S
7.65
EV/EBIT
751.77
EV/EBITDA
119.45
EV/Sales
7.9
The stock's price to book (P/B) is 36% less than its 5-year quarterly average of 5.5 and 30% less than its last 4 quarters average of 5.0
The equity has grown by 32% YoY and by 25% from the previous quarter
BMRN's price to sales (P/S) is 34% less than its 5-year quarterly average of 11.6 and 17% less than its last 4 quarters average of 9.2
The revenue has grown by 16% YoY

Efficiency

How efficient is Biomarin Pharmaceutical business performance
Biomarin Pharmaceutical's ROIC has soared by 118% YoY but it has plunged by 77% from the previous quarter
Biomarin Pharmaceutical's return on sales has surged by 117% YoY but it has shrunk by 76% QoQ

Dividends

What is BMRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BMRN.

Financial health

How did Biomarin Pharmaceutical financials performed over time
The total assets is 193% more than the total liabilities
The total assets has grown by 35% YoY and by 16% from the previous quarter
The debt is 64% smaller than the equity
BMRN's debt to equity is up by 33% year-on-year but it is down by 20% since the previous quarter
The equity has grown by 32% YoY and by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.